CRON:CA:TSX-Cronos Group Inc.

EQUITY | Drug Manufacturers | Toronto Stock Exchange

Last Closing

CAD 21.05

Change

-0.23 (-1.08)%

Market Cap

CAD 7.03B

Volume

0.68M

Analyst Target

CAD 15.09
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-18 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing CRON:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 46.38% 81% B- 96% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 46.38% 81% B- 96% N/A
Trailing 12 Months  
Capital Gain 135.99% 100% F 100% F
Dividend Return N/A N/A N/A N/A F
Total Return 135.99% 100% F 100% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 35.51% 86% B+ 95% A
Dividend Return 35.51% 86% B+ 95% A
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 68.64% 29% F 7% C-
Risk Adjusted Return 51.73% 86% B+ 66% D+
Market Capitalization 7.03B 83% B 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -175.42 100% 98%
Price/Book Ratio 16.98 6% 2%
Price / Cash Flow Ratio -58.47 100% 99%
Price/Free Cash Flow Ratio -29.24 94% 93%
Management Effectiveness  
Return on Equity -9.58% 59% 19%
Return on Invested Capital -11.12% 41% 12%
Return on Assets -8.71% 47% 15%
Debt to Equity Ratio 4.75% 83% 91%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector